PL386051A1 - Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt - Google Patents

Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt

Info

Publication number
PL386051A1
PL386051A1 PL386051A PL38605108A PL386051A1 PL 386051 A1 PL386051 A1 PL 386051A1 PL 386051 A PL386051 A PL 386051A PL 38605108 A PL38605108 A PL 38605108A PL 386051 A1 PL386051 A1 PL 386051A1
Authority
PL
Poland
Prior art keywords
fluorphenyl
enoate
hept
methylsulfonyl
dihydroxy
Prior art date
Application number
PL386051A
Other languages
Polish (pl)
Inventor
Anna Madanecka
Aleksandra Tukalska
Magdalena Grabowska
Original Assignee
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna filed Critical Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna
Priority to PL386051A priority Critical patent/PL386051A1/en
Priority to PCT/PL2009/000084 priority patent/WO2010030201A2/en
Publication of PL386051A1 publication Critical patent/PL386051A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL386051A 2008-09-09 2008-09-09 Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt PL386051A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL386051A PL386051A1 (en) 2008-09-09 2008-09-09 Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
PCT/PL2009/000084 WO2010030201A2 (en) 2008-09-09 2009-09-02 Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL386051A PL386051A1 (en) 2008-09-09 2008-09-09 Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt

Publications (1)

Publication Number Publication Date
PL386051A1 true PL386051A1 (en) 2010-03-15

Family

ID=42005665

Family Applications (1)

Application Number Title Priority Date Filing Date
PL386051A PL386051A1 (en) 2008-09-09 2008-09-09 Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt

Country Status (2)

Country Link
PL (1) PL386051A1 (en)
WO (1) WO2010030201A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200904341A2 (en) * 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Stable pharmaceutical compositions containing rosuvastatin calcium.
TR201009399A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rapidly soluble effervescent rosuvastatin formulations.
US20140179712A1 (en) * 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2016076280A1 (en) 2014-11-11 2016-05-19 塩野義製薬株式会社 Multi-layered tablet containing drug unstable with respect to light

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EA015682B1 (en) * 2005-12-20 2011-10-31 Лек Фармасьютиклз Д.Д. Pharmaceutical composition
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer

Also Published As

Publication number Publication date
WO2010030201A2 (en) 2010-03-18
WO2010030201A3 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
TWI341310B (en) Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt
IS8385A (en) Crystalline form bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5-dihydroxyheptin 6-enoic acid] calcium salt
IS8478A (en) Process for the preparation of the calcium salt of rosuvatatin (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5- dihydroxyhept-6-enoic acid and its crystalline intermediates
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
WO2012147107A3 (en) Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition
SI1873148T1 (en) Pharmaceutical compositions containing crystalline salts of 7-?á4-(4-fluorophenyl)-6-isopropyl-2-?ámethyl(methylsulfonyl)amino?åpyrimidin-5-yl?å-(3R,5S)-3,5-dihydroxyhept-6-enoic acid
MX2011012344A (en) Disaccharin, difumaric acid, di-l-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamin0)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin- 5 -yl) methyl) phenyl)acetate.
FR16C1023I1 (en) 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile salt
IL202363A0 (en) Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP3255043A3 (en) N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3- methylazetidine-1-sulfonamide as chemokine receptor modulator
ZA200807158B (en) Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1, 4-dihydro-8-methoxy-4-oxo-3-quinolinecaroxylic acid
EA201270099A1 (en) TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFTOROMETYL) PHENYL] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO] -2,3,4,5 -TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-IL] METHYL] CYCLOHEXANKARBONIC ACID
PL386051A1 (en) Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
EA200801447A1 (en) PHARMACEUTICAL COMPOSITION
EA201390771A1 (en) METHOD OF OBTAINING PHARMACEUTICAL INTERMEDIATE COMPOUNDS OF HIGH PURITY
PL1704144T3 (en) A method of preparation of the hemi-calcium salt of (e)-7- [4-(4-fluorophenyl)-6-isopropyl-2- [me thyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxy-6-heptenoic acid
WO2012011129A3 (en) Novel polymorph of bis[(e)-7-[4-(4-fluorophenyl)-6-iso-propyl-2-[methyl (methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt
MX2011013149A (en) (s) -2-benzyl-3- ( (3r, 4r) -4- (3 -carbamo ylphenyl) -3, 4-dimethylpiperidinyl) propanoic acid and salt therof as antagonists of the opioid receptors.
UA92467C2 (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
WO2009091346A3 (en) Stable pharmaceutical formulation and preparation methods
ZA200705514B (en) Preparation of pharmaceutical salts of piperazine compounds
UY30336A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACID (E) -7- (4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- (METHYL (METILSULFONIL) AMINO) PIRIMIDIN-5-IL) - (3R, 5S) -3,5-DIHYDROXIHEPT -6-ENOICO AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME
TH133899A (en) Acid sodium salt 5-cyclo-propyl-2 - {[2- (2,6-difluorophenyl) pyrimidin -5-il] amino} benzoic As a DHODH inhibitor

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)